Back to Search
Start Over
Pilot Data on the Feasibility And Clinical Outcomes of a Nomegestrol Acetate Oral Contraceptive Pill in Women With Premenstrual Dysphoric Disorder.
- Source :
-
Frontiers in endocrinology [Front Endocrinol (Lausanne)] 2021 Sep 24; Vol. 12, pp. 704488. Date of Electronic Publication: 2021 Sep 24 (Print Publication: 2021). - Publication Year :
- 2021
-
Abstract
- Background: Up to 80% of reproductive-aged women experience premenstrual symptoms. Premenstrual Dysphoric Disorder (PMDD) is a severe form, affecting 2-5% of women. Combined oral contraceptive pills (COCPs) are used in the treatment of PMDD. Clinical practice suggests that a newer COCP containing nomegestrol acetate (2.5mg) and 17-beta estradiol (1.5mg), may be a suitable treatment for mood symptoms in PMDD.<br />Materials and Methods: This was a clinical follow-up feasibility study of women who had attended the Monash Alfred Psychiatry research centre, Women's Mental Health Clinic, with a diagnosis of PMDD. 67% of the sample also had concurrent cPTSD, 29% co-morbid anxiety, and 20% depression. They were recommended treatment with nomegestrol acetate/17-beta estradiol. Eligible women were contacted by telephone to answer a questionnaire to assess women's subjective response to nomegestrol acetate/17-beta estradiol, acceptability and the Depression, Anxiety and Stress Scale-21 (DASS-21) after being recommended nomegestrol acetate/17-beta estradiol. The paired-sample t-test was used to determine if there were any statistically significant differences in the DASS-21 scores over the study observation period (before and after taking nomegestrol acetate/17-beta estradiol).<br />Results: 35 (74.5%) women reported a subjective positive mood response to nomegestrol acetate/17-beta estradiol, 31 (63.3%) adhered to the medication, and only 10 (20.4%) women reported side effects as the main reason for discontinuing nomegestrol acetate/17-beta estradiol. There were statistically significant reductions ( p< 0.05) in the overall DASS-21 scores from before women commenced nomegestrol acetate/17-beta estradiol and after commencement of treatment.<br />Conclusions: This preliminary study supports the acceptability and effectiveness of nomegestrol acetate/17-beta estradiol as a treatment for mood symptoms in PMDD. Further research, particularly a randomized controlled trial, is required to elucidate the effect of nomegestrol acetate/17-beta estradiol treatment on mood in PMDD.<br />Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.<br /> (Copyright © 2021 Robertson, Thew, Thomas, Karimi and Kulkarni.)
- Subjects :
- Administration, Oral
Adult
Australia epidemiology
Feasibility Studies
Female
Follow-Up Studies
Humans
Middle Aged
Mood Disorders epidemiology
Mood Disorders pathology
Pilot Projects
Prognosis
Contraceptives, Oral, Combined administration & dosage
Megestrol administration & dosage
Mood Disorders drug therapy
Norpregnadienes administration & dosage
Premenstrual Dysphoric Disorder physiopathology
Subjects
Details
- Language :
- English
- ISSN :
- 1664-2392
- Volume :
- 12
- Database :
- MEDLINE
- Journal :
- Frontiers in endocrinology
- Publication Type :
- Academic Journal
- Accession number :
- 34630323
- Full Text :
- https://doi.org/10.3389/fendo.2021.704488